Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind study of HZ-H08905 versus chidamide in relapsed/refractory peripheral T-cell lymphoma
CTR20242024Phase 3Active
- Sponsor
- Hezheng Pharma
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HZ-H08905, tucidinostat in peripheral T-cell lymphoma (PTCL), sponsored by Hezheng Pharma. Started Aug 2024; status: active.
02
Drugs
HZ-H08905tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20242024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242024.